Provider review
MEDVi tirzepatide review
What MEDVi charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on MEDVi’s own pages on November 21, 2026: brand Zepbound for a $99 membership plus the medication cost. It scores 39/100 under our written v4.1 scoring guide, #22 of 22 programs scored, with an open FDA warning letter (721455).
What is distinctive about this programme
Two figures we will not assert
Our source dataset flags MEDVi's $399 tirzepatide rate as not appearing on the current GLP-1 landing page, and its $369 oral semaglutide rate as third-party reporting rather than a direct capture. We have imported both as pending rather than reported, which means they do not appear in any ranking or comparison on this site.
That is the correct handling and it is also the useful information: a price that cannot be found on the provider's own page is not a price a patient can rely on. Verify at intake.
Escalating pricing at higher doses
The tirzepatide programme is reported as a refill rate at lower doses reaching $499 at 10, 12.5 and 15 mg. If accurate, that places it among the most expensive compounded programmes in the market at exactly the doses most patients reach — well above brand Zepbound at $449 direct from LillyDirect.
Introductory rates
The $179 first-month semaglutide rate rises to $299 ongoing, and the $249 first-month oral rate to $369. Both are excluded from our rankings, as all introductory rates are.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $299 | Provider-reported |
| Semaglutide oral / ODT | $369 | Verification pending |
| Tirzepatide injectable | $399 | Verification pending |
Where it holds up
- Publishes a refill rate structure rather than a single ambiguous figure
- Semaglutide ongoing pricing is clearly stated
Where it does not
- Tirzepatide pricing could not be found on the current landing page and is marked pending
- Reported escalation to $499 at maintenance doses exceeds brand Zepbound direct
- Introductory first-month rates are substantially below ongoing rates
- Oral semaglutide figure is third-party reported rather than captured
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $299/mo, month-to-month |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| MEDVi | month_to_month | compounded injectable | not recorded | $399 | not verified | $399 | Recurring | Verification pending | not recorded |
| MEDVi | month_to_month | compounded injectable | not recorded | $299 | not verified | $299 | Recurring | Provider-reported | 2026-07-06 |
| MEDVi | month_to_month | compounded oral / ODT | not recorded | $369 | not verified | $369 | Recurring | Verification pending | not recorded |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where MEDVi sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is MEDVi the cheapest option?
Read on its own page on November 21, 2026: brand Zepbound for a $99 membership plus the medication cost; the compounded price did not render in the page’s HTML (an empty price placeholder).
Is compounded tirzepatide the same as Zepbound?
MEDVi scores 39/100 under the written v4.1 scoring guide, #22 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is total annual cost (0 of 20).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Best Tirzepatide Providers Online in 2026Pillar / Money
- Best Month-to-Month Tirzepatide ProgramsPillar / Money
Related coverage
- LillyDirect: what we hold
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Times
- FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Management
- The Wegovy Pill Passed Three Million Prescriptions in Just Over Five Months
- Zepbound Now Carries an Obstructive Sleep Apnoea Indication Alongside Weight Management
- Oral Tirzepatide and Sublingual Products: What Evidence Exists?
- Peptide Therapy: What Is Approved, What Is Compounded, and What Is Not a Medicine
GLP-1 Tirzepatide Review. “MEDVi Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/medvi/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.